US FDA’s Marks Was Frustrated About Slow Completion Of 2021 Comirnaty Review

CBER Director Peter Marks told Janet Woodcock in an email that he thought reviewers were treating the BLA for the first fully approved COVID-19 vaccine as a conventional review or learning exercise.

stopwatch
OVRR officials initially proposed completing the Comirnaty BLA review by 15 September 2021. • Source: Shutterstock

A top US Food and Drug Administration official was frustrated with the pace of the review of Pfizer Inc./BioNTech SE’s COVID-19 vaccine Comirnaty in 2021, and appeared to push for the application to be approved several weeks earlier than staff wanted, agency emails reveal.

The trove of messages released by the agency show Center for Biologics Evaluation and Research Director Peter Marks telling...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet